xglp + glucagon + gastrin

xglp + glucagon + gastrin is an investigational **peptide-based tri-agonist** that simultaneously activates the glucagon-like peptide-1 receptor, glucagon receptor, and cholecystokinin 2 receptor (CCK-2R). The drug is designed as a long-acting molecule with pronounced anti-diabetic and anti-obesity activity, shown to reduce body weight and hepatic lipid content more effectively compared to dual agonists and liraglutide in preclinical models[1][6]. Mechanistically, xglp + glucagon + gastrin achieves potent and selective activation of these three receptors, resulting in improved glycemic control, increased pancreatic beta-cell mass, and restoration of pancreas function primarily via cAMP accumulation and ERK1/2 phosphorylation pathways[1][6]. The molecule represents an integrated approach to metabolic disease treatment, combining the metabolic effects of GLP-1 and glucagon (energy expenditure, weight loss, insulin secretion) with gastrin’s (CCK-2R) ability to enhance beta-cell growth and survival[1][2][3][4].

Other names

xGLP-1/GCG/gastrinxGLP/GCG/gastrin